Jazz Pharmaceuticals plc SEC filings JAZZ
Jazz Pharmaceuticals plc has 1,002 filings in SEC EDGAR's recent list, going back to Jun 20, 2017. Its latest annual report, Form ARS, was filed on Jun 8, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 2, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 2, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Jul 14, 2026 | — |
| DEFA14A | Additional proxy material | Jun 8, 2026 | — |
| DEF 14A | Proxy statement | Jun 8, 2026 | Jul 23, 2026 |
| PRE 14A | Preliminary proxy statement | May 29, 2026 | Jul 23, 2026 |
| DEFA14A | Additional proxy material | Jul 14, 2025 | — |
| DEFA14A | Additional proxy material | Jul 10, 2025 | — |
| DEFA14A | Additional proxy material | Jun 6, 2025 | — |
| DEF 14A | Proxy statement | Jun 6, 2025 | Jul 24, 2025 |
| PRE 14A | Preliminary proxy statement | May 23, 2025 | Jul 24, 2025 |
| DEFA14A | Additional proxy material | Jul 22, 2024 | — |
| DEFA14A | Additional proxy material | Jun 14, 2024 | — |
| DEF 14A | Proxy statement | Jun 14, 2024 | Jul 25, 2024 |
| PRE 14A | Preliminary proxy statement | Jun 3, 2024 | Jul 25, 2024 |
| DEFA14A | Additional proxy material | Jul 26, 2023 | — |
| DEFA14A | Additional proxy material | Jun 16, 2023 | — |
| DEF 14A | Proxy statement | Jun 16, 2023 | — |
| PRE 14A | Preliminary proxy statement | Jun 6, 2023 | — |
| DEFA14A | Additional proxy material | Jul 22, 2022 | — |
| DEFA14A | Additional proxy material | Jul 15, 2022 | — |
| DEFA14A | Additional proxy material | Jul 7, 2022 | — |
| DEFA14A | Additional proxy material | Jun 17, 2022 | — |
| DEFA14A | Additional proxy material | Jun 13, 2022 | — |
| DEF 14A | Proxy statement | Jun 13, 2022 | Jul 28, 2022 |
| PRE 14A | Preliminary proxy statement | May 31, 2022 | Jul 28, 2022 |
| DEF 14A | Proxy statement | Aug 30, 2021 | Sep 23, 2021 |
| PRE 14A | Preliminary proxy statement | Aug 19, 2021 | Sep 23, 2021 |
| DEFA14A | Additional proxy material | Jul 26, 2021 | — |
| DEFA14A | Additional proxy material | Jul 15, 2021 | — |
| DEFA14A | Additional proxy material | Jul 14, 2021 | — |
| DEFA14A | Additional proxy material | Jul 14, 2021 | — |
| DEFA14A | Additional proxy material | Jun 11, 2021 | — |
| DEF 14A | Proxy statement | Jun 11, 2021 | Jul 29, 2021 |
| PRE 14A | Preliminary proxy statement | Jun 1, 2021 | Jul 29, 2021 |
| DEFA14A | Additional proxy material | Jul 22, 2020 | — |
| DEFA14A | Additional proxy material | Jul 21, 2020 | — |
| DEFA14A | Additional proxy material | Jun 12, 2020 | — |
| DEF 14A | Proxy statement | Jun 12, 2020 | Jul 30, 2020 |
| PRE 14A | Preliminary proxy statement | Jun 2, 2020 | Jul 30, 2020 |
| DEFA14A | Additional proxy material | Jun 14, 2019 | — |
| DEFA14A | Additional proxy material | Jun 14, 2019 | — |
| DEF 14A | Proxy statement | Jun 14, 2019 | Aug 1, 2019 |
| DEFA14A | Additional proxy material | Jun 15, 2018 | — |
| DEFA14A | Additional proxy material | Jun 15, 2018 | — |
| DEF 14A | Proxy statement | Jun 15, 2018 | Aug 2, 2018 |
| DEFA14A | Additional proxy material | Jun 20, 2017 | — |
| DEFA14A | Additional proxy material | Jun 20, 2017 | — |
| DEF 14A | Proxy statement | Jun 20, 2017 | Aug 3, 2017 |
Showing 47 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JAZZ (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Ireland
- Headquarters
- Dublin
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1232524
- Former names
- JAZZ PHARMACEUTICALS INC (until Jan 18, 2012)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.